AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Wyomingnewsnow Tv

Published November 13, 2026 · Updated November 14, 2026

Trump administration advances ibogaine, other experimental mental health treatments

Read the full story at Wyomingnewsnow Tv

The department will invest up to $4.9 million over five years to advance the powerful psychoactive drug ibogaine as a potential treatment for post-.

Post on X

Share this story

Surfaced by this Google Alert

Ibogaine